Purissima Produces Cannabinoids Using Algae Fermentation

Purissima revealed that its platform can produce more than 70 compounds, many of which are minor cannabinoids as well as new plant-powered chemistries with potential therapeutic value.
Purissima revealed that its platform can produce more than 70 compounds, many of which are minor cannabinoids as well as new plant-powered chemistries with potential therapeutic value.
Photo 224263243 © Liudmila Moseichuk | Dreamstime.com

Purissima has developed the scalability of its proprietary and multi-patented production platform of cannabinoids using algae fermentation.

Related: Allmicroalgae Expands Production for its Algae-based Ingredients

Additionally, Purissima revealed that its platform can produce more than 70 compounds, many of which are minor cannabinoids as well as new plant-powered chemistries with potential therapeutic value. The company forecasts the first wave of products featuring its ingredients will reach the market before the summer of 2022.

Purissima aims to identify and biosynthesize compounds on a mass scale in a controlled laboratory setting with microalgae strains. The potential use of these cannabinoids includes wellness, pharmaceutical, beauty and skin care, and food and nutrition sectors. According to the company, immediate applications of these ingredients include combatting skin conditions and concerns such as decreasing inflammation, reducing pain, treating infection and more. 

"The microalgae that enable all of this innovation and subsequent scientific applications possible was selected from more than 10,000 potential strains," said Robert Evans, Purissima co-founder, and chief business and strategy officer. "We have identified the ideal single-cell organism that serves as the vehicle to yield some of the purest, most effective compounds available today, while also preserving Earth's biodiversity in the process and vastly reducing manufacturing costs."

"What makes our recent achievements even more remarkable is that we have now proven that we can create libraries of unique natural and novel biotherapeutics, scale their production, and thus enable the development of diverse consumer applications and pharmacological pipelines," said George Rudenko, Purissima co-founder, and chief executive and technology officer. "Our technology bypasses nature's work by dramatically reducing a traditional, multi-month 'crop cycle' to just a few days, and makes a step forward in bringing unimaginable diversity of natural compounds from rare medicinal plants, all while preserving their natural habitats. What is more compelling is the ability to combine compounds in novel ways allows the creation of truly unique and natural bioactives."

More in Launches & Claims